XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 101.61

Change

-0.82 (-0.80)%

Market Cap

N/A

Volume

7.64M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.64 (-0.41%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.50 (-0.68%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.94 (-0.83%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.36 (-0.40%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.27 (-1.07%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.13 (-0.34%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.92 (-0.94%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.36 (-1.21%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.20 (-0.68%)

USD 0.01B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

+0.04 (+0%)

USD 0.04B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.80% 67% D+ 69% C-
Dividend Return 0.13% 20% F 2% F
Total Return 13.93% 57% F 62% D
Trailing 12 Months  
Capital Gain 39.27% 90% A- 86% B+
Dividend Return 0.18% 17% F 2% F
Total Return 39.44% 90% A- 84% B
Trailing 5 Years  
Capital Gain 22.85% 33% F 58% F
Dividend Return 0.50% 28% F 1% F
Total Return 23.35% 29% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 2.44% 33% F 48% F
Dividend Return 2.53% 33% F 38% F
Total Return 0.08% 26% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 32.92% 19% F 30% F
Risk Adjusted Return 7.67% 24% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.